Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
| Published: | January 5, 2011 |
|---|---|
| Feature: | Op-Ed |
| Forum: | open for comment; 6 Comments posted |
Funding unpredictability in human embryonic stem-cell research inflicts a heavy cost on all scientific progress, says professor William Sahlman.
Published in 2010
From Bench to Board: Gender Differences in University Scientists' Participation in Commercial Science
| Authors: | Waverly W. Ding, Fiona Murray, and Toby E. Stuart |
|---|---|
| Published: | September 15, 2010 |
| Paper Release Date: | August 2010 |
| Feature: | Working Papers |
Does gender affect whether a university scientist will be invited to work with for-profit companies? Indeed it does. A new paper finds that male professors receive more opportunities than their female counterparts to join scientific advisory boards and start new companies. Research, focusing on the biotechnology field, was conducted by Haas School of Business professor Waverly W. Ding, MIT Sloan professor Fiona Murray, and HBS professor Toby E. Stuart.
Boundary Spanning in a For-Profit Research Lab: An Exploration of the Interface Between Commerce and Academe
| Authors: | Christopher C. Liu and Toby E. Stuart |
|---|---|
| Published: | September 9, 2010 |
| Paper Release Date: | August 2010 |
| Feature: | Working Papers |
In science-based industries, innovation requires bridging the boundary between universities and companies. As entrepreneurial faculty venture into the world of commerce by building relationships and reputations in industry, company researchers and dealmakers seek access to the distributed knowledge base that resides within the community of scholars. But what happens within organizations when scientists venture deeply into the world of academe? In this look at one influential life sciences company, Christopher C. Liu of the Rotman School of Management and Toby E. Stuart of Harvard Business School find important connections between publishing, the allocation of rewards within the company, and the structure of the communication network inside and beyond the borders of the organization.
Published in 2008
Long-Tail Economics? Give Me Blockbusters!
| Published: | September 10, 2008 |
|---|---|
| Feature: | Research & Ideas |
Although the Long Tail theory might argue otherwise, HBS marketing professor John Quelch believes in the power of blockbusters to excite consumers, motivate salespeople, and attract top talent.
Creating Leaders for Science-Based Businesses
| Published: | August 27, 2008 |
|---|---|
| Feature: | HBS Centennial Colloquia Reports |
The unique challenges of managing and leading science-based businesses—certain to be a driver of this century's new economy—demand new management paradigms. At Harvard Business School, the opportunities start just across the street. From HBS Alumni Bulletin.
Published in 2007
The FDA: What Will the Next 100 Years Bring?
| Q&A with: | Arthur A. Daemmrich |
|---|---|
| Published: | September 24, 2007 |
| Feature: | Research & Ideas |
With the possible exception of the Internal Revenue Service, no other governmental agency touches the lives of more Americans than the U.S. Food and Drug Administration, which ensures the safety of $1.5 trillion worth of consumer goods and medicines. Harvard Business School professor Arthur A. Daemmrich discusses the impact and challenges of the agency and his new book, Perspectives on Risk and Regulation: The FDA at 100.
Health Care Under a Research Microscope
| Published: | May 30, 2007 |
|---|---|
| Feature: | Research & Ideas |
Perhaps no industry has caught the research attention of Harvard Business School faculty as much as health care. Researchers are investigating business-focused solutions on everything from improving team work among surgical teams to developing market motivations that increase the use of water purification in poor villages.
Published in 2006
Science Business: What Happened to Biotech?
| Q&A with: | Gary P. Pisano |
|---|---|
| Published: | November 13, 2006 |
| Feature: | Research & Ideas |
After thirty years the numbers are in on the biotech business—and it's not what we expected. The industry in aggregate has lost money. R&D performance has not radically improved. The problem? In a new book, Professor Gary Pisano points to systemic flaws as well as unhealthy tensions between science and business.
The Hidden Market for Babies
| Q&A with: | Debora L. Spar |
|---|---|
| Published: | February 13, 2006 |
| Feature: | Research & Ideas |
Surrogates. Fertility clinics. Egg donors. Adoption. It's time to recognize (and perhaps regulate) the huge market being created by reproductive technologies, says HBS professor Debora L. Spar. She discusses her new book, The Baby Business.
Published in 2003
Why Europe Lags in Pharmaceuticals and Biotech
| Published: | December 8, 2003 |
|---|---|
| Feature: | Research & Ideas |
Governmental, cultural and academic differences are hurting Europe’s chances of gaining on the U.S. Can anything be done?
Making Biotech Work as a Business
| Published: | January 13, 2003 |
|---|---|
| Feature: | Research & Ideas |
What will it take for biotechnology to fulfill its economic potential? Participants need to think twice about the strategies and assumptions that are driving the industry, says HBS professor Gary P. Pisano.
Published in 2000
The Business of Biotech
| Published: | August 7, 2000 |
|---|---|
| Feature: | Research & Ideas |
On the cusp of what most analysts agree will be the age of biotechology, Professor Gary P. Pisano and four HBS alums on the front lines of the biotech revolution offer their views of the challenges, issues and opportunities facing the industry in the laboratory, the boardroom and the marketplace.
